Menu
Conformis is a medical technology company that uses its proprietary iFit® Image-to-Implant® technology platform to develop, manufacture, and sell joint replacement implants and instruments that are individually sized and shaped, which Conformis refers to as personalized, individualized, or sometimes as customized, to fit each patient's unique anatomy. Conformis offers a broad line of sterile, personalized knee and hip implants and single-use instruments delivered to hospitals and ambulatory surgical centers. In clinical studies, the Conformis iTotal® CR knee replacement system demonstrated superior clinical outcomes, including better function and greater patient satisfaction, compared to traditional, off-the-shelf implants. Conformis owns or exclusively in-licenses issued patents and pending patent applications that cover personalized implants and patient-specific instrumentation for all major joints.
Conformis, Inc. (NASDAQ:NASDAQ:CFMS) Q4 2022 Results Conference Call March 1, 2023 4:30 PM ETCompany ParticipantsMark Augusti - President and Chief Executive OfficerBob Howe - CFO and…
ConforMIS press release (CFMS): Q4 GAAP EPS of -$0.51.Revenue of $17.4M (+13% Y/Y).Product revenue of $14.2 million, a decrease of 7% year-over-year on a reported basis and 6% on…
BILLERICA, Mass. (AP) — BILLERICA, Mass. (AP) — ConforMIS Inc. (CFMS) on Wednesday reported a loss of $3.7 million in…
BILLERICA, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) an orthopedic medical device company that features personalized knee and hip replacement products, announced today financial results for the fourth quarter and year ended December 31, 2022.
BILLERICA, Mass., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), an orthopedic medical device company that features personalized knee and hip replacement products, announced today that Mark Augusti, Chief Executive Officer, and Bob Howe, Chief Financial Officer, will participate at two upcoming investor conferences.
A share of Conformis Inc. (NASDAQ:CFMS) closed at $1.74 per share on Friday, down from $1.75 day before. While Conformis Inc. has underperformed by -0.57%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, CFMS fell by -89.53%, with highs and lows ranging from $18.77 to $1.20, […]
